title: Rash from EGFR inhibitors: opportunities and challenges for palliation.
abstract: The epidermal growth factor receptor (EGFR) inhibitors represent a relatively new class of cancer agents that also provide new challenging side effects for cancer patients. This article reviews the clinical aspects of EGFR inhibitor-induced rash, which occurs most commonly with use of these agents, and discusses some of the challenges faced in attempting palliation treatment.
authors.affiliation: Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. jatoi.aminah@mayo.edu.
authors.forename: Benjamin M
authors.initials: BM
authors.lastname: Solomon
authors.forename: Aminah
authors.initials: A
authors.lastname: Jatoi
mesh_terms: D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005076:Exanthema / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications* / Q000188:drug therapy*; D010166:Palliative Care; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*
chemical_list: D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors
references.citation: Clin Cancer Res. 2005 Sep 15;11(18):6414-21
references.pmid: 16166415
references.citation: Nat Rev Cancer. 2006 Oct;6(10):803-12
references.pmid: 16990857
references.citation: JAMA. 2003 Oct 22;290(16):2149-58
references.pmid: 14570950
references.citation: J Clin Oncol. 2004 Apr 1;22(7):1201-8
references.pmid: 14993230
references.citation: Oncologist. 2007 May;12(5):577-83
references.pmid: 17522246
references.citation: Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):34-6
references.pmid: 18154217
references.citation: FEBS Lett. 2006 Mar 20;580(7):1859-64
references.pmid: 16516204
references.citation: Br J Dermatol. 2002 Sep;147(3):598-601
references.pmid: 12207609
references.citation: Photodermatol Photoimmunol Photomed. 2007 Feb;23(1):42-5
references.pmid: 17254038
references.citation: Cancer Biol Ther. 2006 Apr;5(4):340-2
references.pmid: 16808060
references.citation: Clin Cancer Res. 2007 Jul 1;13(13):3913-21
references.pmid: 17606725
references.citation: Curr Oncol Rep. 2006 Jul;8(4):269-74
references.pmid: 17254526
references.citation: J Support Oncol. 2006 May;4(5):236-8
references.pmid: 16724647
references.citation: Can Fam Physician. 2002 Apr;48:712-6
references.pmid: 12046366
references.citation: J Clin Oncol. 2007 May 20;25(15):1960-6
references.pmid: 17452677
references.citation: Br J Dermatol. 2001 Jun;144(6):1169-76
references.pmid: 11422037
references.citation: Cancer Res. 2002 Sep 1;62(17):4922-8
references.pmid: 12208742
references.citation: Arch Dermatol. 1998 Apr;134(4):454-8
references.pmid: 9554297
references.citation: Clin Exp Dermatol. 2008 Jan;33(1):46-9
references.pmid: 17983455
references.citation: Eur J Cancer. 2007 Mar;43(5):845-51
references.pmid: 17289377
references.citation: Biochim Biophys Acta. 2007 Apr;1770(4):687-93
references.pmid: 17276010
references.citation: J Clin Oncol. 2007 Dec 1;25(34):5390-6
references.pmid: 18048820